Opendata, web and dolomites

NovLeuReg

Identification and characterization of novel essential regulators of acute myeloid leukemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovLeuReg project word cloud

Explore the words cloud of the NovLeuReg project. It provides you a very rough idea of what is the project "NovLeuReg" about.

malignancy    screens    governing    shrna    optimism    mechanisms    enzyme    independent    marks    world    regulator    performing    dna    exploring    hematopoietic    therapy    immature    sequencing    leukemic    leukemia    acute    helin    skills    scientific    interacting    expertise    nature    inhibition    cancer    functions    expert    biochemistry    hydroxylates    realization    deficient    cell    supervised    broaden    newly    abnormal    null    regulators    throughput    frequent    setd5    mouse    uncovered    normal    leukemogenesis    prof    regulation    methylated    modifying    revealed    molecular    reversible    acquiring    maintenance    cytosines    kristian    pathogenic    phenomenon    genomics    epigenetic    functional    biology    pharmacological    depletion    genes    proliferation    raised    insights    enzymes    transferable    plan    firstly    accomplishment    chromatin    amenability    mutations    highlight    cells    drug    somatic    myself    researcher    myeloid    therapies    candidates    tet2    epigenetics    models   

Project "NovLeuReg" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.bric.ku.dk/research/helin_group/
 Total cost 212˙194 €
 EC max contribution 212˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2018-09-02

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 212˙194.00

Map

 Project objective

Acute myeloid leukemia is a hematopoietic malignancy characterized by the abnormal proliferation of immature myeloid cells. The implementation of high-throughput sequencing revealed that somatic mutations in various epigenetic regulators represent a frequent pathogenic phenomenon in leukemogenesis. This raised optimism for the development of new therapies in leukemia due to the reversible nature of epigenetic marks and amenability of chromatin-modifying enzymes to pharmacological inhibition. However, realization of this potential requires further research into epigenetic mechanisms governing the maintenance of leukemic cells. The overall goal of the proposed work is to characterize novel important epigenetic regulators in leukemic cells and to assess their potential as drug targets. Firstly, I plan to identify and study epigenetic regulators essential for leukemic cells deficient in TET2, an enzyme that hydroxylates methylated cytosines in DNA. This will be achieved by performing state-of-the-art shRNA screens in mouse Tet2-null leukemia models and by exploring the functions of the uncovered candidates using a range of cell biology, biochemistry, and functional genomics approaches. The second aim is to investigate the molecular functions of SETD5, a newly-uncovered epigenetic regulator of leukemic cells. This will be achieved by identifying its target genes and interacting partners in leukemic cells and by exploring the effects of its depletion on normal and cancer cells. The accomplishment of both research aims will provide new insights into epigenetic regulation of leukemic cells and highlight novel drug targets for future therapy development. The project will be supervised by Prof Kristian Helin, a world-leading expert in the field of epigenetics and cancer. Through this work, I aim to broaden my scientific expertise by acquiring numerous technical and transferable skills and to establish myself as an independent researcher in the field of cancer epigenetics.

 Publications

year authors and title journal last update
List of publications.
2016 Aliaksandra Radzisheuskaya, Daria Shlyueva, Iris Müller, Kristian Helin
Optimizing sgRNA position markedly improves the efficiency of CRISPR/dCas9-mediated transcriptional repression
published pages: e141-e141, ISSN: 0305-1048, DOI: 10.1093/nar/gkw583
Nucleic Acids Research 44/18 2019-04-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVLEUREG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVLEUREG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

POSPORI (2019)

Polymer Optical Sensors for Prolonged Overseeing the Robustness of civil Infrastructures

Read More  

Goc-MM (2019)

Human gut microbiota on gut-on-a-chip

Read More  

ACES (2019)

Antarctic Cyclones: Expression in Sea Ice

Read More